MiR-613 blocked the progression of cervical cancer by targeting LETM1
H. Ji, N.-J. Hu Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China. jirujing2010@163.com
OBJECTIVE: The purpose of this study was to investigate the potential effects of miR-613 on the development of cervical squamous cell cancer (CSCC) and the relevant mechanism.
PATIENTS AND METHODS: The expression level of miR-613 was detected in CSCC tissues and cells by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Thereafter, online prediction software and Luciferase reporter assays were used to evaluate the possible target of miR-613, and the effects of the miR-613 on SiHa cells were determined in vitro. Then, the changes of protein expression in cells were measured by Western blot. Finally, Cell Counting Kit-8 (CCK-8), wound healing and transwell assays were performed to analyze cell proliferation, invasion, and migration.
RESULTS: It was found that compared with that in normal tissues and cells, miR-613 expression was found suppressed in CSCC tissues and cells. Based on bioinformatics and Luciferase results, miR-613 could target and bind to LETM1. Besides, it was found that miR-613 could regulate the expression of LETM1 in SiHa cells, and miR-613 had a valuable suppressive effect on the proliferation, invasion, and migration of SiHa cells through the subsequent experiments. However, when co-transfection of miR-613 mimics and LV-LETM1 into SiHa cells, the anti-cancer effects of miR-613 on SiHa cells vanished.
CONCLUSIONS: Taken all, this research discovered the function of miR-613 on CSCC by targeting LETM1, revealing that miR-613/LETM1 signal pathway might be a potential therapeutic target for the diagnosis and treatment of CSCC.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
H. Ji, N.-J. Hu
MiR-613 blocked the progression of cervical cancer by targeting LETM1
Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 12
Pages: 6576-6582
DOI: 10.26355/eurrev_202006_21642